Trial · NCT03441555
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tmax of venetoclax | Approximately 32 days after first dose of study drug | Time to maximum plasma concentration (Tmax) of venetoclax |
| Primary | Clearance of Alvocidib | Approximately 32 days after first dose of study drug | Clearance (CL) of alvocidib |
| Primary | AUC0-∞ of Alvocidib | Approximately 32 days after first dose of study drug | Area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) post-dose of alvocidib |
| Primary | Cmax of Venetoclax | Approximately 32 days after first dose of study drug | Maximum plasma concentration (Cmax) of venetoclax |
| Primary | Half-life (t1/2) of Alvocidib | Approximately 32 days after first dose of study drug | Half-life (t1/2) of alvocidib |
| Primary | AUC0-24 Post-dose of Venetoclax | Approximately 32 days after first dose of study drug | Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax. |
| Primary | Cmax of Alvocidib | Approximately 32 days after first dose of study drug | Maximum plasma concentration (Cmax) of alvocidib. |
| Primary | AUCt Post-dose of Alvocidib | Approximately 32 days after first dose of study drug | Area under the plasma concentration-time curve from time zero to time t (AUCt) post-dose alvocidib. |
| Primary | Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for Venetoclax and Alvocidib | Minimum first cycle of dosing (up to 28 days) | RPTD will be determined using available safety and pharmacokinetics data upon completion of the dose escalation phase. |
| Secondary | Complete Response (CR) Rate | Up to approximately 8 months | CR is defined as the proportion of participants with documented complete response (CR) based on International Working Group (IWG) criteria. |
| Secondary | Combined CR Rate | Up to approximately 8 months | Combined CR rate is defined as CR + CRi (CR with incomplete blood count recovery) based on IWG criteria. |
| Secondary | Objective Response Rate (ORR) | Up to approximately 18 months | ORR is defined as the proportion of participants with documented partial response (PR) or better based on IWG criteria. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03441555/registered